T1	Participants 325 367	Seventy immunocompromised febrile patients
T2	Participants 433 476	vancomycin therapeutic drug monitoring grou
T3	Participants 569 586	patient follow-up
T4	Participants 740 752	all patients
T5	Participants 953 975	TDM and control groups
T6	Participants 1327 1346	patient population.
T7	Participants 1613 1643	patient management in patients
